Results 291 to 300 of about 39,021 (326)

Liquid biopsy in genitourinary cancers: Diagnostic and prognostic implications. [PDF]

World J Clin Oncol
Youssef J, Yehya A, Salhab Z, Bitar R, Ghamlouche F, Bahmad HF, Abou-Kheir W.   +6 more
europepmc   +1 more source

Clinical utility of circulating tumor DNA for early detection of recurrence after curative hepatectomy in patients with colorectal cancer with liver metastases: A prospective observational study protocol (CASSIOPEIA). [PDF]

PLoS One
Inoue A, Morimoto Y, Nishizawa Y, Hashimoto M, Ozato Y, Furukawa K, Hirota M, Miyazaki Y, Tomokuni A, Motoori M, Fujitani K.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

ctDNA: Moving toward Clinical Utility

Cancer Discovery, 2022
Abstract Findings from the phase II DYNAMIC study suggest that circulating tumor DNA analyses could help clinicians decide whether patients with stage II colon cancer require chemotherapy after standard surgery. Liquid biopsies could also shed light on the development of resistance to KRASG12C inhibition, paving the way for better ...
openaire   +2 more sources

Chasing ctDNA in Patients With Sarcoma

American Society of Clinical Oncology Educational Book, 2020
Liquid biopsies are new technologies that allow cancer profiling of tumor fragments found in body fluids, such as peripheral blood, collected noninvasively from patients with malignancies. These assays are increasingly valuable in clinical oncology practice as prognostic biomarkers, as guides for therapy selection, for treatment monitoring, and for ...
Catherine C, Coombs, Tony, Dickherber, Brian D, Crompton   +2 more
openaire   +2 more sources

Dynamic Treatment Stratification Using ctDNA

2019
An accurate profiling of the genomic landscape is mandatory to establish the best clinical and therapeutic approach for patients with solid malignancies. Moreover, tumor cells constantly adapt to external pressures-i.e., systemic treatment-with the selection and expansion of resistant subclones and the emergence of heterogeneous overlapping genomic ...
Joana, Vidal, Alvaro, Taus, Clara, Montagut   +2 more
openaire   +2 more sources

ctDNA-Monitoring beim frühen Brustkrebs

Onkologische Welt, 2021
Der Nachweis von zirkulierender Tumor-DNA (ctDNA) nach neoadjuvanter Chemotherapie mit oder ohne Pembrolizumab wurde in der Studie I-SPY 2 bei Hochrisikopatientinnen mit frühem Brustkrebs als Biomarker für Ansprechen und fernmetastasenfreies Überleben (RFS) identifiziert.
openaire   +1 more source

ctDNA als Prognosemarker beim DLBCL

Im Fokus Onkologie, 2019
Zirkulierende Tumor-DNA (ctDNA) wird derzeit immer wieder als prognostischer Marker diskutiert. Gerade beim diffusen groszelligen B-Zell-Lymphom (DLBCL) ware ein solcher von grosem Wert, da die Behandlungsergebnisse immer noch schwer vorherzusagen sind.
Christian Behrend, Stefanie Kreutmair, Lena Illert   +2 more
openaire   +1 more source

Adjuvant Immunotherapy Best for ctDNA+ Bladder Cancer

Cancer Discovery, 2021
Abstract A liquid biopsy may help identify patients with operable urothelial cancer who stand to benefit from adjuvant immunotherapy. In the IMvigor010 study, patients who tested positive for circulating tumor DNA showed improvement in disease-free survival and overall survival if they received adjuvant atezolizumab instead of ...
openaire   +2 more sources

Enrichment and Analysis of ctDNA

2019
ctDNA provided by liquid biopsy offers a promising alternative to tumor biopsy as it gives a non-invasive and «real-time» access to the cancer genome and reflects tumor intra and extra heterogeneity. ctDNA has shown growing clinical interest for cancer diagnosis, prognosis, theragnostics, therapeutic monitoring, and clonal evolution tracking.
openaire   +3 more sources

Methods for Measuring ctDNA in Lymphomas

2018
Plasma cell-free DNA (cfDNA) is an easily accessible source of tumor DNA that allows accurate profiling of lymphoma patients, representing a complementary source of tumor DNA to tissue biopsy for genotyping. Applications of cfDNA analysis in lymphomas include: (1) identification of tumor mutations in a biopsy-free manner; (2) tracking tumor clonal ...
Rossi, Davide, Condoluci, Adalgisa, Spina, Valeria, Gaidano, Gianluca   +3 more
openaire   +3 more sources